Cytonics CYT-108: A Unique Approach to OA Treatment
In this interview, we spoke with Joey Bose, President & CEO of Cytonics, diving into the intricacies of their...
Pfizer Tivdak SLA Accepted by FDA for Priority Cervical Cancer Review
Genmab A/S and Pfizer Inc. announced the FDA’s acceptance of the supplemental Biologics License Application (sBLA) to potentially convert...
ICON Sets Financial Forecast for 2024 Full Year
ICON plc, a global clinical research organization, has projected financial targets for the year ending December 31, 2024. The...
FDA NIH & DARPA Government Agencies Lead New DCT Initiatives
In today’s discussion, we’re joined by Craig Lipset, Co-Chair of the Decentralized Trials & Research Alliance (DTRA), who shares...
Master Protocols: FDA New Flexible Approach in Cancer Trials
Master Protocols (MPs) mark a significant evolution in the realm of clinical research, especially notable in oncology. These protocols,...
Innovative Merck-Inspirna Deal: New Hope in Cancer Battle
Merck KGaA, Darmstadt, Germany, has entered into a licensing agreement with Inspirna, Inc., New York, for the development of...
A Great Divide: Sponsors Clash With FDA on Trial Data Excess
A new study, conducted collaboratively by the Tufts Center for the Study of Drug Development (Tufts CSDD), the FDA,...
Clinical Trial GCP Focus: Powerful QA Strategies Revealed
One of the most well-received presentations from Momentum Events’ December 2023 2nd GCP Inspection Readiness Conference was Tony Johnson,...
Revolutionary J-Brain Cargo® Tech in JCR Alexion Deal
JCR Pharmaceuticals Co., Ltd. has entered into a Research Collaboration, Option, and License Agreement with Alexion, AstraZeneca Rare Disease,...
FDA Unveils Groundbreaking Rare Disease Guidance Document
In a landmark move, the U.S. Food and Drug Administration (FDA) has released a detailed guidance document titled “Rare...